David MEEK joined Ipsen as CEO in July 2016. He holds a BA in Management from the University of Cincinnati and started his career at Johnson & Johnson and Janssen Pharmaceutica (1989-2004).
He then joined Novartis (2005-2012), as the global business franchise head for the respiratory and dermatology in Switzerland; President and CEO of Novartis Canada; and Head of oncology for Northern, Central and Eastern Europe, in Italy. From 2012 to 2014, he served as CCO of Endocyte, a U.S. biotech company.
He was also EVP and President of the oncology division of Baxalta Inc., which was acquired by Shire.
